Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care

Fang Wu,Yue Zeng,Joel W. Neal

DOI: https://doi.org/10.21037/tlcr-24-540

2024-10-31

Translational Lung Cancer Research

Abstract:Fang Wu 1,2 , Yue Zeng 1 , Joel W. Neal 2 1 Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China; 2 Division of Oncology, Department of Medicine, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA Comment on: Lu S, Kato T, Dong X, et al . Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med 2024;391:585-97. Keywords: Non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); osimertinib; consolidation; LAURA Submitted Jun 23, 2024. Accepted for publication Aug 14, 2024. Published online Oct 28, 2024. doi: 10.21037/tlcr-24-540 Chemoradiotherapy (CRT) followed by consolidation durvalumab is the current standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) (1). However, for tumors with epidermal growth factor receptor ( EGFR ) mutation, this may not be an ideal option. In the post-hoc analysis of the EGFR-mutated subgroup from PACIFIC trial, involving a limited number of 35 patients, progression-free survival (PFS) and overall survival (OS) were not improved when receiving durvalumab after CRT campared with placebo group (2). Osimertinib is recommended as first-line treatment for advanced NSCLC and as adjuvant therapy for resected NSCLC with EGFR mutation (3,4). There are limited data regarding the consolidation of EGFR tyrosine kinases inhibitors (TKIs) for unresectable stage III EGFR-mutated NSCLC. The LAURA trial is a phase 3, double-blind, placebo-controlled trial, to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable EGFR-mutated NSCLC (exon 19 deletion or exon 21 L858R point mutation, alone or with other EGFR mutations). Patients were randomized to receive either osimertinib or placebo group after completing CRT. The primary endpoint was PFS as assessed by blinded independent central review. Recently, Lu et al. reported the interim analysis of LAURA trial. In patients with unresectable stage III EGFR-mutated NSCLC, consolidation osimertinib after CRT led to impressively prolonged PFS, marking a paradigm shift in the treatment of locally advanced EGFR-mutant NSCLC (5). What insights can the LAURA trial offer clinicians? Was placebo an appropriate control? Durvalumab is approved in the same patient population regardless of EGFR mutation status. However, it is not an acceptable standard of care—as demonstrated by the lack of effect of immunotherapy in metastatic EGFR-mutated NSCLC, a retrospective study suggests favorable results with osimertinib (6), and high rates of synergistic toxicity when osimertinib is given to patients with disease recurrence within 6 months of the last dose of durvalumab (7). Therefore, osimertinib is the only appropriate consolidation therapy that should be considered for EGFR mutant NSCLC and placebo control was appropriate for this study. Is changing practice based on PFS appropriate? Yes—the improvement in PFS was dramatic, with a hazard ratio of 0.16, mirroring that was seen in ADAURA trial for surgically resected stage II (0.17) and IIIa (0.12) and much better than durvalumab in PACIFIC trial (0.52) (1,4). But should we wait for OS data? OS was not significantly improved at this interim analysis, but at progression on placebo, 81% of patients received osimertinib. This population should not be compared to FLAURA directly, because frequent mandated surveillance scans—including magnetic resonance imaging (MRI) scan (MRI's)—would have detected low disease burdens of metastatic recurrence, which we expect to be sensitive to osimertinib for a longer duration than the 18.9 months median PFS (3). Therefore, we would not expect OS to be positive based on this study design, and would not wait for further data for using this therapy in practice tomorrow. Is appropriate to use indefinite osimertinib treatment following CRT? Perhaps surprisingly, it appears that only a minority of patients in LAURA—probably fewer than 10%—have long term disease-free survival without osimertinib. Indefinite treatment may also offer advantages in protecting against intracranial metastases, a common site of recurrence in the control arm which did undergo routine surveillance brain MRI's. However, it also raises concerns such as potential side effect and increased cost burden. While some patients will discontinue due to side effects or personal preference, we hope that eventually ultrasensitive methods of residual tumor detection, likely either circulating tumor DNA molecular residual disease testing, or more sensitive imaging, could identify those in whom it is safe to discontinue and proceed with observation alone, because they may actually be cured, or alternatively, identify early signs of progression to restart therapy -Abstract Truncated-

oncology,respiratory system